Brief: Regeneron Provides Update On Phase 3 Trial Of Fianlimab (Lag-3 Inhibitor) Combination In First-Line Unresectable Or Metastatic Melanoma
16/05/2026 01:24
May 16 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: REGENERON PROVIDES UPDATE ON PHASE 3 TRIAL OF FIANLIMAB (LAG-3 INHIBITOR) COMBINATION IN FIRST-LINE UNRESECTABLE OR METASTATIC MELANOMA REGENERON PHARMACEUTICALS: TRIAL DID NOT REACH STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT OF IMPROVEMENT IN PROGRESSION-FREE SURVIVAL (PFS) Source text: ID:nGNX999tvN Further company coverage: REGN.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)